Gastrointestinal Device-Mediated Delivery of mRNA-LNPs: Implications for Reporter Assays and Therapeutic Development

Study Background and Research Question

Messenger RNA (mRNA) therapeutics have rapidly emerged as a promising strategy for treating chronic diseases and preventing infectious diseases, including applications in cancer immunotherapy, metabolic disorders, and pandemic response. Despite the clinical success of mRNA-lipid nanoparticles (LNPs) via parenteral injection, challenges persist—particularly the need for trained healthcare personnel, injection-associated pain, and patient compliance issues. The optimal pharmacokinetic and biodistribution profile of mRNA therapies often hinges on the administration route, yet alternative delivery strategies remain underexplored. This gap motivated Schultz et al. to investigate whether ingestible microjet devices could enable effective, needle-free GI wall delivery of mRNA-LNPs, and how this mode of administration might modify expression and biodistribution patterns compared to conventional injection routes.

Key Innovation from the Reference Study

The reference study pioneers the evaluation of device-mediated mRNA-LNP delivery into the gastric and intestinal walls using a microjet injector. While ingestible devices for small molecule and peptide drugs have been previously described, this work is among the first to systematically assess the expression and systemic biodistribution of mRNA-LNPs delivered via such a route in both mice and minipigs. Notably, the authors used firefly luciferase mRNA as a sensitive bioluminescent reporter to quantitatively track transgene expression and distribution in vivo, providing a robust model for both basic research and translational development.

Methods and Experimental Design Insights

The experimental workflow began with the formulation of mRNA-LNPs encapsulating in vitro transcribed firefly luciferase mRNA, a widely used bioluminescent reporter mRNA. The LNPs were characterized for stability, encapsulation efficiency, and transfection potency before and after exposure to the jet injection process. Jetting was performed at 8 bar backing pressure, and physicochemical properties such as particle size, polydispersity index (PDI), surface charge, and mRNA encapsulation were closely monitored. For in vivo studies, the team delivered mRNA-LNPs directly into the gastric or intestinal wall in both mice and minipigs using the microjet device, with control groups receiving intramuscular (IM), intravenous (IV), or subcutaneous (SC) injections. Expression of the luciferase enzyme was monitored via luminescence imaging and quantified across various tissues and plasma samples at multiple time points.

Protocol Parameters

• mRNA-LNP formulation: Firefly luciferase mRNA encapsulated using established LNP protocols; encapsulation efficiency and physicochemical integrity validated before and after jetting.
• Jet injection parameters: 8 bar backing pressure; nozzle diameter 254 μm; delivery into gastric or intestinal submucosa.
• Animal models: BALB/c mice and Göttingen minipigs, selected for translational relevance in GI physiology.
• Reporter detection: In vivo bioluminescence imaging and tissue luminescence assays to quantify luciferase expression kinetics and spatial distribution.
• Comparative controls: IM, IV, and SC injection groups to benchmark biodistribution and expression profiles.

Core Findings and Why They Matter

Schultz et al. demonstrated that GI wall delivery of mRNA-LNPs via microjet resulted in both local and systemic expression of the reporter gene, with mRNA and protein detected in plasma and lymph nodes alongside the site of injection. Notably, the biodistribution profile following stomach or intestinal wall administration differed from that of IM, IV, or SC injection, indicating that GI wall targeting may facilitate broader systemic exposure while also supporting local mucosal immunity. The physicochemical integrity and transfection efficiency of the LNPs were retained after jet injection, supporting the compatibility of this approach with existing mRNA-LNP formulations.

These findings are significant for two main reasons. First, they establish ingestible GI wall injection devices as a viable, needle-free alternative for mRNA delivery, potentially increasing patient compliance and enabling self-administration. Second, the altered biodistribution profile suggests possible advantages for vaccination strategies or therapies targeting mucosal tissues or systemic immunity, warranting further investigation in disease models and human studies.

Comparison with Existing Internal Articles

Internal literature on firefly luciferase mRNA highlights the molecule’s value as a reporter for gene expression assay, cell viability assay, and in vivo imaging due to its high sensitivity and robust bioluminescent output. For instance, one internal article emphasizes the benefits of ARCA capping and modified nucleotides (5mCTP, ΨUTP) for improved mRNA stability and immune evasion, streamlining reporter workflows. The present reference study builds on this foundation by demonstrating that advanced formulation strategies—such as those used for Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP)—are compatible with physical delivery via jet injection, preserving both LNP integrity and functional expression in vivo.

Another internal analysis (see here) discusses troubleshooting and optimization of bioluminescent reporter mRNA workflows, including LNP formulation for enhanced transfection and imaging. The reference study supports these recommendations, showing that even after the mechanical stress of jetting, LNP-encapsulated luciferase mRNA maintains its performance, thereby extending the potential for such assays into new administration routes.

Limitations and Transferability

While the results are promising, several limitations should be considered. Species-specific differences between mice, minipigs, and humans may affect biodistribution and immune response to mRNA-LNPs. The study primarily uses a reporter gene model rather than therapeutic mRNA, so further work is needed to confirm efficacy in disease contexts. Additionally, long-term safety, repeated dosing, and the performance of various mRNA modification chemistries via GI device delivery are yet to be addressed. Nonetheless, the successful use of bioluminescent reporter mRNA in this context provides a valuable platform for preclinical optimization of device-mediated mRNA therapies.

Why this cross-domain matters, maturity, and limitations

The translation of ingestible device-mediated delivery from the context of reporter-based biodistribution studies to potential therapeutic and vaccine applications is supported by the preserved integrity and robust expression of LNP-encapsulated mRNA across administration routes. This cross-domain bridge is foundational for the future development of oral or minimally invasive mRNA medicines, although clinical translation will require validation in human models and for various therapeutic payloads.

Research Support Resources

For researchers aiming to replicate or extend these workflows, commercially available Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) can be a critical resource for assay development and delivery optimization. This reagent, offered by APExBIO (SKU R1005), incorporates ARCA capping and nucleotide modifications, resulting in enhanced stability, high translational efficiency, and minimized innate immune activation. When paired with lipid nanoparticle formulation and advanced delivery modalities such as microjet injection, it enables rigorous evaluation of gene expression, cell viability, and in vivo imaging in a variety of preclinical models. Adhering to recommended handling protocols—such as maintaining cold-chain storage, minimizing freeze-thaw cycles, and using RNase-free materials—will help ensure experimental reproducibility and integrity.